Hims & Hers Health, Inc.

HIMS Healthcare Drug Manufacturers Specialty & Generic

Hims & Hers Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 59.0% from fiscal 2024. In the quarter to June 2026, revenue grew 38.3%, EPS fell 294.7%, free cash flow grew 5.09% and total debt rose 40.8%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

28.07 1.31 −4.46%
Market cap
$6.9B
P/E
0.0×
Fwd P/E
−213×
Dividend yield
—
F-score
4/9
Altman Z
4.10
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
0.00 0.00 56.96 94.53

+8 more quarters

P/S ratio
3.12 2.00 3.11 5.81
P/FCF ratio
96.77 59.47 98.76 95.88
P/Operating CF
(223.56) 53.05 119.14 86.33
P/B ratio
24.79 10.63 13.50 22.10
EV/Sales
3.32 2.09 3.28 5.96
EV/EBITDA
0.00 118.84 47.35 83.39
EV/FCF
103.09 62.27 104.10 98.43
Current Ratio
0.93 1.69 1.90 1.88
Net Debt/EBITDA
(7.97) (4.08) 13.96 11.41
Debt/Equity
4.21 2.18 1.80 1.67
Earnings Yield
(1.76%) (0.24%) 1.76% 1.06%
Free Cash Flow Yield
1.03% 1.68% 1.01% 1.04%
Free Cash Flow per Share
(0.27) 0.26 0.01 0.37
Book value per Share
1.40 1.95 2.40 2.57
Free Cash Flow
(61.86) 59.51 1.92 83.46
EV/EBIT
0.00 0.00 72.90 114.58
Other line items

Show all line items

Columns are period end dates